A phase II trial of trebaninib (AMG 386), a selective angiopoietin 1/2 neuralizing peptibody in patients with persistent/recurrent carcinoma of the endometrium: A Gynecologic Oncology Group study

2015 ◽  
Vol 137 ◽  
pp. 24 ◽  
Author(s):  
K.N. Moore ◽  
M. Sill ◽  
M.E. Tenney ◽  
C.J. Darus ◽  
D. Griffin ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Recurrent Carcinoma ◽  
Amg 386 ◽  
Angiopoietin 1

Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (A Gynecologic Oncology Group Study)

1989 ◽  
Vol 161 (2) ◽  
pp. 309-312 ◽  
Author(s):  
Gregory P. Sutton ◽  
John A. Blessing ◽  
Neil Rosenshein ◽  
Guy Photopulos ◽  
Philip J. DiSaia
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Oncology Group Study

Phase II Trial of Pyrazoloacridine in Patients with Persistent or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

2002 ◽  
Vol 84 (2) ◽  
pp. 241-244 ◽  
Author(s):  
Steven C. Plaxe ◽  
John A. Blessing ◽  
Nader Husseinzadeh ◽  
Kenneth D. Webster ◽  
Janet S. Rader ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Oncology Group Study
Sign in / Sign up

Export Citation Format

Share Document